LungenClinic Grosshansdorf GmbH

The site focuses on developing and validating advanced diagnostic tools and therapeutic devices for lung diseases.

• Development of imaging biomarkers for early detection of lung cancer
• Evaluation of minimally invasive bronchoscopy technologies
• Assessment of novel pulmonary function testing platforms

Research aims to improve early diagnosis and optimize treatment delivery for patients with non‑small cell lung cancer and other respiratory conditions.

Trials investigate innovative surgical and endoscopic procedures for resectable lung tumors.

• Video‑assisted thoracoscopic surgery (VATS) for stage I–II NSCLC
• Robotic‑assisted lobectomy outcomes
• Peri‑operative imaging guidance to reduce margins

The goal is to enhance surgical precision and reduce postoperative complications in patients undergoing curative resection of lung cancer.

The clinic examines lymphatic involvement in thoracic malignancies to improve staging and treatment planning.

• Study of mediastinal lymph node staging accuracy
• Impact of lymphatic drainage patterns on metastatic spread
• Biomarker profiling of lymphatic endothelial cells in cancer

Efforts aim to refine staging and guide adjuvant therapy decisions for advanced NSCLC.

The core research portfolio targets a broad spectrum of thoracic cancers, especially multiple subtypes of lung cancer.

• ALK‑positive and RET‑fusion positive NSCLC targeted therapy trials
• KRAS G12C mutant lung cancer investigational agents
• Small‑cell lung cancer immunotherapy combinations
• Adjuvant strategies for resected non‑squamous NSCLC

Studies are designed to test new systemic treatments, improve survival, and personalize therapy based on molecular profiling of neoplasms.

Research includes metabolic complications associated with cancer and chronic lung disease.

• Cachexia management in advanced lung cancer
• Metabolic profiling of patients receiving targeted therapies
• Nutrition‑support interventions during chemoradiation

The aim is to mitigate weight loss and improve quality of life for patients with cancer‑associated cachexia and metabolic disturbances.

The largest focus area, covering both malignant and non‑malignant lung conditions.

• Chronic obstructive pulmonary disease (COPD) exacerbation reduction trials
• Progressive pulmonary fibrosis treatment studies
• Early‑stage NSCLC screening and treatment pathways
• Large‑cell neuroendocrine carcinoma therapeutic evaluation

Objectives range from preventing disease progression to testing novel agents that extend survival for patients with respiratory tract diseases.

The clinic participates in public‑health initiatives linked to lung disease risk and prevention.

• Air‑quality monitoring impact on COPD incidence
• Smoking‑cessation program effectiveness
• Population‑based lung cancer screening feasibility

These projects aim to reduce environmental risk factors and promote early detection to lower the burden of lung disease in the community.

Recognizing psychosocial aspects, trials address mental health and behavior in patients undergoing lung cancer treatment.

• Psychological support interventions during chemoradiation
• Assessment of anxiety and depression in COPD patients
• Behavioral strategies to improve medication adherence

Research seeks to enhance patient resilience and treatment adherence, ultimately improving outcomes for those with lung cancer and chronic respiratory illnesses.